Summit Therapeutics (SMMT) Income from Non-Controlling Interests (2023 - 2024)
Summit Therapeutics' (SMMT) quarterly Income from Non-Controlling Interests came in at $11000.0 in Q1 2024, down 98.86% YoY from $968000.0 in Q2 2023, and down 59.26% on a QoQ basis from $27000.0 in Q4 2023.
Summit Therapeutics (SMMT) Income from Non-Controlling Interests (2023 - 2024) Analysis & Trends
Summit Therapeutics (SMMT) has 2 years of Income from Non-Controlling Interests data on file, last reported at $11000.0 in Q1 2024.
- Quarterly Income from Non-Controlling Interests fell 98.86% year-over-year to $11000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was -$921000.0 (down 195.14% YoY) and the FY2023 annual result came in at $36000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests declined to $11000.0 in Q1 2024, from $27000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $968000.0 in Q1 2023 to a low of -$965000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Sep 30, 2023 | 6,000.00 |
| Jun 30, 2023 | -965,000.00 |
| Mar 31, 2023 | 968,000.00 |